Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pure Bioscience (PURE)

Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported...

PURE : 0.0467 (-6.04%)
PURE Bioscience, Inc. Announces Leadership Promotions

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE” or the “Company”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today announced that...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal 2025 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal 2023 Second Quarter And Six-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal First Quarter 2023 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal 2022 Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal 2022 Third Quarter and Nine-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period...

PURE : 0.0467 (-6.04%)
PURE Bioscience Reports Fiscal 2022 Second Quarter And Six-Month Financial Results

PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal second quarter and six-month period...

PURE : 0.0467 (-6.04%)

Barchart Exclusives

This Dividend ETF Has Crushed the S&P 500 in 2025. Should You Buy It Before 2026?
After trouncing the S&P 500 this year, FDD looks best approached gradually or on pullbacks, since most of the easy upside is likely behind it and future returns will probably come from steadier dividends and slower price appreciation rather than another explosive rally. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar